INTRODUCTION
About 5% of deliveries involve loss of over 1 liter of blood.
1,2 Women with this degree of blood loss generally develop moderate to severe postpartum anemia. With non severe and non life-threatening postpartum anemia, iron supplementation is generally prescribed, but with severe and life-threatening anemia erythrocyte transfusions can be needed. [2] [3] [4] Post hemorrhagic postpartum anemia is thought to contribute to a variety of morbidities, such as lethargy, lactation failure, and postpartum depression. [1] [2] [3] Administering rEpo to women with posthemorrhagic postpartum anemia has been proposed as a means of hastening their increase in hematocrit and diminishing any attendant morbidity. 2, 5 However, the practice of administering rEpo to these women does not appear to have been widely adopted, possibly because its effectiveness requires additional clarification. To provide clarification, we evaluated, individually and in aggregate, all published reports describing rEpo administration to women with postpartum anemia.
MATERIALS AND METHODS Study Identification and Assessment
Guidelines of the Cochrane Collaborative Handbook were used to identify relevant studies. 6 Briefly, the search was initiated by reviewing personal files, after which the identified studies and all subsequently retrieved articles were scanned for additional references. In addition, Medline was searched from January 1990 to December of 2002 using the following search terms: rEpo, Epo, postpartum, women, and anemia. No language restrictions were applied. All studies that reported rEpo administration to women with postpartum anemia and investigated its effect on hemoglobin correction, rate of transfusion or adverse events were considered eligible. The publications not satisfying inclusion criteria were either review articles or those that did not address the population and the outcomes mentioned.
Statistical Considerations
Summary tests were used to determine the relationship between rEpo administration and hemoglobin increase after delivery. Exact methods were used for hypothesis testing using Microsoft Excel 2000 (Microsoft Office 2000, SR1 Professional). The estimate of the effect size on hemoglobin concentration increase at days 4 to 7 and 14 was obtained in a common metric measure for each study. 7 This value was obtained from the studies if the authors had reported the mean±SD of the hemoglobin of experimental and control groups at days 0, 4 to 7, and 14 after delivery (or the mean±SD increase in hemoglobin concentration at days 4 to 7, and 14), and the number of patients included in each group. A fixed model was assumed to estimate a common ''real'' effect size across the studies. The magnitude of the effect of rEpo treatment would be represented by the summary measure of effect size and by the 95% CI if the hypothesis of homogeneity of effect across the studies was not rejected. The variation between studies was estimated with a Q-test statistic; the criterion of a p-value <0.05 was used to reject the null hypothesis of homogeneity. 7, 8 
RESULTS
A total of 12 publications were retrieved. 2, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Of these, two 2,9 were summaries of previous studies and contained no original data. Two were published in languages other than English 10,11 and these were obtained and translated. One was not located after an exhaustive search including attempts to contact the journal and the authors. 12 Eight publications 10, [13] [14] [15] [16] [17] [18] [19] were randomized controlled trials, and one 11 was a case series report. Features of the nine evaluable studies 10,11,13 -19 are summarized in Table 1 , listed in chronological order of publication. The reports involved a total of 480 women; 300 rEpo recipients and 180 controls. The number of patients included in each study ranged from 5 to 95. The doses of rEpo used ranged from 60 to 300 U/kg/ day. Three studies used intravenous rEpo administration only (studies 4,5,9), two used subcutaneous administration only (studies 7 and 8), two used both routes (studies 1 and 2), and two contrasted intravenous administration in some subjects with subcutaneous administration in others (studies 3 and 6). The time between delivery and the first dose of rEpo ranged from 24 to 96 hours. All studies included iron administration (160 to 200 mg/ day) orally, but three had unique features; studies 4 and 6 used intravenous iron as a first dose (400 and 100 mg/kg/day, respectively) and then resumed the same oral administration as the other studies, and study 9 used intravenous iron (200 mg/ kg/day) in groups 1 and 2 during 4 days before beginning oral iron.
All studies except one (study 8) were randomized clinical trials (Table 2) , but only studies 4, 5 and 9 were placebo-controlled, and only study 4 was double-blinded. Study 3 used historical controls since its main focus was to compare two different doses and routes of rEpo administration. In study 5, follow-up of the patients was limited to 5 days, since the authors were primarily interested in the short-term effect of rEpo on mental status and attitude.
The mean age of the women in the studies ranged from 24 to 30 (reported in studies 2,3,5 and 6), the parity range was similar and varied between 1.5 and 1.8 (reported in studies 2,5 and 7). The subjects did not differ in the mode of delivery (reported in studies 2,5 and 9). Inclusion and exclusion criteria of the nine reports were similar. One intention of the rEpo treatment was to reduce postpartum transfusions. Indeed, none of the 300 rEpo recipients received erythrocyte transfusion, while two of the 180 controls were transfused. Another intention of the rEpo treatment was to achieve a faster correction of the postpartum anemia. Table 3 displays a summary of these results. The effect size of rEpo treatment at 4 to 7 and 14 days after beginning treatment was calculated by metaanalysis, using the five studies that could be analyzed (studies 2, 4 to 6 and 9). However, variation among the studies was too large to be attributed to chance (p<0.01 for the Q-test statistic). Therefore, the summary effect size of rEpo on hemoglobin concentration could not be estimated. The following variables were considered as possible sources of variation; hemoglobin level at study entry, total rEpo dose, route of rEpo administration, and iron dose and route of administration. Further exploration of the statistical heterogeneity according to the characteristics of the methodology was limited by the small number of reports available and diversity of the designs.
At 4 to 7 days after rEpo treatment was begun, a significant erythropoietic effect (based on increase in reticulocytes) was generally reported. However, by day 14, the reticulocyte counts in rEpo-treated and control subjects were not different from each other. In study 7, the maximum increase in reticulocyte count was observed on day 15 .
In all studies, the administration of rEpo was related to a corresponding decrease in ferritin levels. Intravenous iron (studies 4,6 and 9) appeared to increase the iron stores for a short interval (4 to 7 days). No significant adverse effects of rEpo treatment were reported. Occasional complaints included local irritation at the injection site (study 2), transient unilateral leg paresthesia (study 4), and a transient warm sensation (study 9). A metallic-like taste was also reported in study 9 likely due to the iron administration. Studies 2 and 3 reported an increase in platelet count without any associated thromboembolic events. 
DISCUSSION
We performed this analysis to clarify whether administering rEpo to women with postpartum anemia results in higher hemoglobin concentrations and fewer transfusions, with a favorable safety profile. Among the 480 study subjects, postpartum erythrocyte transfusions were so rare that summary statistics were not meaningful. Individual studies consistently reported that rEpo administration to women with postpartum anemia increased the hemoglobin concentration more rapidly than did control (placebo or no treatment). However, marked heterogeneity in outcomes of the various reports prevented the use of summary statistics to quantify and assess the level of confidence in that improvement. One area of heterogeneity between the various studies was the method of iron supplementation used. Previous studies have shown that rEpo effectiveness relies on iron availability, and that rEpo use can lead to iron deficiency. 20, 21 Oral iron supplementation might not prevent the appearance of iron deficiency during rEpo treatment of women with posthemorrhagic postpartum anemia. Intravenous iron (sucrose iron) administration has been described in the setting of anemia of pregnancy as an effective and safe way to treat or to prevent iron deficiency. 22, 23 However, we observed no clear relationship between iron dose and effectiveness of rEpo in these women.
Another difference in the studies was the severity of postpartum anemia at study entry. Intuitively, women with the most perinatal blood loss and the lowest postpartum hemoglobin concentrations are those at greatest risk for needing a postpartum transfusion. Thus, women with average blood losses at delivery are not likely to develop severe postpartum anemia, and rEpo treatment would probably not be particularly useful in such patients. Perhaps women with severe posthemorrhagic postpartum anemia who, for any reason, are not treated with transfusions might be good candidates for future rEpo trials. Also, maternal Epo levels vary during pregnancy and immediately after delivery, but the usual correlation between hemoglobin and Epo is evident mainly during the third trimester. 2, 24 Acute and chronic bleeding during pregnancy has been associated with a significant increase in erythropoietin levels. 25 However, data obtained from Breymann et al 17 suggested that a certain group of women, whose Epo production might be blunted by proinflammatory cytokines, had a better response to administration of rEpo.
We observed a wide range in the doses of rEpo used, from 60 to 300 U/kg/day, and from 300 U/kg/course to 3000 U/kg/course. However, no clear dose-response relationship was established between rEpo dose and rate of rise in hemoglobin concentration.
No significant adverse effects of rEpo were evident in this population. However, hypertension has been reported in at least one pregnant subject with impaired renal disease after the use of rEpo. 26 Thus, although rEpo treatment appeared to be safe in the setting of postpartum anemia, definitive conclusions could not be reached regarding very rare but significant safety issues.
Previous studies have suggested that the erythropoietic action of rEpo is better with daily doses than with an equivalent weekly dose given once or twice weekly. 27 This fact is relevant for women with postpartum anemia cared for on an outpatient basis. The need for frequent rEpo dosing in future clinical trials might be alleviated by using long-acting rEpo preparations, such as Darbepoietin alfa, an erythropoietic stimulating protein having pharmacodynamic effects similar to rEpo but requiring less frequent dosing. [28] [29] [30] [31] In summary, our analysis suggests that rEpo administration to women with postpartum anemia appears to be safe and is associated with a trend toward a faster elevation of hemoglobin concentration. However, its efficacy in terms of diminishing postpartum transfusions is unproven, because of the rarity of transfusions in the reported studies.
Reducing transfusion is not the only benefit to consider when evaluating the usefulness of postpartum rEpo treatment. Selected women with postpartum anemia might receive a substantial benefit by more rapidly correcting their anemia. It is difficult from the present analysis to know precisely how to identify such women prospectively, and how to council them regarding the risks and benefits or rEpo treatment. Quantifying blood loss at delivery is imprecise, and perhaps a hemoglobin or hematocrit below a certain level, either before or after delivery, could be part of a screening method. The present analysis suggests that the short-term risks of rEpo treatment in this population are negligible, but the benefits remain incompletely defined. Therefore, rEpo administration to women with posthemorrhagic postpartum anemia cannot be endorsed as an evidence-based therapy.
